Skip to content

Meditation-Relaxation (MR Therapy) for Sleep Paralysis.

Meditation-Relaxation (MR Therapy) for Sleep Paralysis: A Pilot Study in Patients With Narcolepsy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04483310
Acronym
MR_Therapy
Enrollment
20
Registered
2020-07-23
Start date
2018-12-01
Completion date
2022-12-31
Last updated
2020-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Narcolepsy Type 1, Sleep Paralysis

Keywords

Behavioral Treatment, Sleep Paralysis, Narcolepsy Type 1

Brief summary

The aim of the study is to evaluate, with a small-scale pilot study, the efficacy of Meditation Relaxation therapy for Sleep Paralyses in patients with narcolepsy. The study involves two arms, with intervention with Meditation Relaxation therapy or sham over a period of three months.

Interventions

BEHAVIORALMR therapy.

MR therapy is based on 4 steps applied directly during the attack: Step I: Reappraisal of the meaning of the attack; Step II: psychological and emotional distancing; Step III: inward focused-attention meditation; Step IV: Muscle relaxation.

BEHAVIORALbreathing-distraction exercise

The control intervention is based on a breathing exercise, the patients should entail slow deep breaths, while repeatedly counting from 1-10

Sponsors

Azienda Usl di Bologna
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Narcolepsy (type 1 and 2) based on polysomnography, Multiple Sleep Latency Test \[MLST\] and CSF hypocretin level testing). * Patients had to have experienced SP at least four times in the last month.

Exclusion criteria

* Psychiatric comorbidity.

Design outcomes

Primary

MeasureTime frameDescription
Sleep Paralysis Experiences and Phenomenology Questionnaire (SP-EPQ)Three months.The questionnaire addresses the distress associated with SP.

Secondary

MeasureTime frameDescription
Daily journalThree months.Each day during the study (12 weeks), participants rated their SP occurrence, perceived duration (sec./min.), fear associated with SP, and disturbance caused by hallucinations (on a ten-point scale).

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026